Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion
Diabetes mellitus schwächt die Antwort auf Anti-CD20-Therapie bei primärer membranöser Nephropathie trotz gleichwertiger B-Zell-Depletion
Nephrology Dialysis Transplantation · 30.10.2026 · 41 (11) · 1988-1998
DOI: 10.1093/ndt/gfag065 ↗Auf einen Blick
Bei primärer membranöser Nephropathie war die Remission unter Anti-CD20-Therapie bei Patient:innen mit Diabetes mellitus später seltener als ohne Diabetes. Die B-Zell-Depletion war vergleichbar.
Fragestellung
Beeinflusst Diabetes mellitus das Ansprechen auf eine Anti-CD20-Antikörpertherapie bei primärer membranöser Nephropathie?
Methode
Retrospektive Kohortenstudie mit Propensity-Score-Matching (1:2) bei Erwachsenen mit primärer MN nach mindestens einem vollständigen Kurs Anti-CD20-Therapie.
Ergebnisse
Nach Matching 207 Patient:innen (72 MN + DM, 135 MN). Remission nach 9 Monaten: 94 % vs. 77 %, OR 4,55 (95 %-KI 1,52–12,50); nach 12 Monaten: 97 % vs. 86 %, OR 5,26 (95 %-KI 1,25–20,00).
Schlussfolgerung der Autor:innen
Trotz vergleichbarer B-Zell-Depletion zeigten MN-Patient:innen mit Diabetes mellitus eine geringere Response auf die Anti-CD20-Antikörpertherapie als nondiabetische Patient:innen.
Kernaussagen
- B-Zell-Depletion und immunologische Remission unterschieden sich nicht signifikant.
- Klinische Remission war bei Diabetes nach 9 und 12 Monaten seltener.
- Die Sicherheitsprofile waren zwischen den Gruppen ähnlich.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.03.2026. Verfasst von Xiaomeng Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, B-Lymphocytes, Antigens, CD20, Lymphocyte Depletion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fourth Military Medical University, Department of Science and Technology of Shaanxi Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and hypothesis Primary membranous nephropathy (MN) and diabetes mellitus (DM) are common comorbidities, yet the impact of DM on the response to anti-CD20 monoclonal antibody therapy in MN remains unclear. We hypothesized that despite comparable B-cell depletion, MN patients with comorbid DM would exhibit a reduced treatment response compared to nondiabetic MN patients.
Methods
In this retrospective cohort study, we included adults with primary MN who received at least one complete course of anti-CD20 antibody therapy. Propensity score matching (1:2) was applied based on age, sex, baseline estimated glomerular filtration rate, urinary protein, and PLA2R antibody status. The primary outcome was remission (complete or partial) of proteinuria at 3, 6, 9, and 12 months. Secondary outcomes included immunological remission, B-cell depletion, and changes in renal parameters. Multivariable logistic regression, Kaplan–Meier analysis, and subgroup analyses were used to compare outcomes between MN patients with (MN + DM) and without diabetes (MN).
Results
After matching, 207 patients were included (72 MN + DM, 135 MN). B-cell depletion and immunological remission rates showed no statistically significant differences between groups over the 12-month follow-up period. However, MN patients had significantly higher overall remission rates at 9 months [94% vs. 77%; odds ratio (OR) = 4.55, 95% confidence interval (CI) = 1.52–12.50, P < 0.01] and at 12 months (97% vs. 86%; OR: 5.26, 95% CI: 1.25–20.00, P < 0.05). Subgroup analyses confirmed consistently poorer responses in diabetic patients across multiple strata. Safety profiles were similar between groups.
Conclusion
Despite equivalent B-cell depletion, MN with DM patients show a reduced response to anti-CD20 antibody therapy relative to nondiabetic patients, underscoring that tight glycemic control, early supplementary anti-CD20 dosing for poor response, and combined immunosuppressive regimens may enhance their clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
ORCID-Profile: Xiaomeng Xu, Mengting Wu, Fang Zhao, Jipeng Li, Ye Chen, Rui Lu, Yang Zha, Yuting Zhang, Hongbin Peng, Haichao Cao, Lijie He
Förderung
- Fourth Military Medical University
- Department of Science and Technology of Shaanxi Province
Zitieren
APA
Xu, X., Wu, M., Zhao, F., Li, J., Chen, Y., Lu, R., Zha, Y., Zhang, Y., Peng, H., Cao, H., & He, L. (2026). Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion. Nephrology Dialysis Transplantation, 41(11), 1988-1998. https://doi.org/10.1093/ndt/gfag065
Vancouver
Xu X, Wu M, Zhao F, Li J, Chen Y, Lu R, et al. Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion. Nephrology Dialysis Transplantation. 2026;41(11):1988-1998. doi:10.1093/ndt/gfag065
BibTeX
@article{Xu2026,
author = {Xu, Xiaomeng and Wu, Mengting and Zhao, Fang and Li, Jipeng and Chen, Ye and Lu, Rui and Zha, Yang and Zhang, Yuting and Peng, Hongbin and Cao, Haichao and He, Lijie},
title = {Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {11},
pages = {1988--1998},
doi = {10.1093/ndt/gfag065}
}
EUVIMED